Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP and Ibritumomab Tiuxetan in Elderly DLBCL
NCT00058422Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2003
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Overall Survival at 2 years, Progression-free Survival at 2 years and 2 more. Started Feb 2003; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00058422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058422.